TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23541299

Group type: EXPERIMENTAL
Intervention: In-office screening tool for assessing fitness to drive
Number of subjects: 1230
Study: 23541331

Group type: EXPERIMENTAL
Intervention: Surgical, unilateral carotid body resection
Number of subjects: 1
Study: 23542776

Group type: EXPERIMENTAL
Intervention: Combined trunk and gluteal NMES
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no NMES)
Number of subjects: 7
Study: 23542823

Group type: EXPERIMENTAL
Intervention: Fecal microbial transplantation (FMT) - freshly prepared fecal enemas daily for 5 days
Number of subjects: 10
Study: 23543609

Group type: EXPERIMENTAL
Intervention: Triazoles (62.7%) and echinocandins (34.2%) were the most commonly used antifungal agents; first-line therapy was typically fluconazole (37.7%).
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: First-line antifungal susceptibility.
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Treatment initiated after diagnostic confirmation in 166/268 (61.9%) patients.
Number of subjects: 306
Study: 23543660

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg daily for 18 to 24 months)
Number of subjects: 21
Study: 23544203

Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis system (with the system on and a 1-to-1 mapping of spatial information)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Residual vision
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis system (with the system on but with randomly scrambled spatial information)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Normal spatial information (follow-up testing)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Scrambled spatial information (follow-up testing)
Number of subjects: 28
Study: 23545055

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study: 23545708

Group type: EXPERIMENTAL
Intervention: Exendin-(9,39) at 30 pmol/kg/min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Exendin-(9,39) at 300 pmol/kg/min
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GLP-1-(9,36)amide
Number of subjects: 4
Study: 23547075

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a dose range of 24 to 54 Gy in six fractions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 102
Study: 23547218

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 2 × 500 mg added to current biologic and nonbiologic DMARD treatment
Number of subjects: 176
Study: 23547558

Group type: EXPERIMENTAL
Intervention: OM-174 (600, 800, or 1000 μg/m²) administered as intravenous infusion, twice weekly for a total of 5, 10, or 15 injections.
Number of subjects: 17
Study: 23547655

Group type: EXPERIMENTAL
Intervention: Nilotinib (average daily dose of at least 720 mg)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Biphasic response to nilotinib
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Slow monophasic response to nilotinib
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: BCR-ABL1 (IS) ≤ 10% at 6 months
Number of subjects: 123
Study: 23547778

Group type: EXPERIMENTAL
Intervention: Opportunistic infections (OIs) in the prior three months
Number of subjects: 1094

Group type: COMPARATOR
Intervention: No opportunistic infections (OIs) in the prior three months
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Comparison of CD4+ T cell count changes
Number of subjects: 1094
Study: 23547837

Group type: EXPERIMENTAL
Intervention: Alemtuzumab consolidation after fludarabine-based induction
Number of subjects: 0
Study: 23548165

Group type: EXPERIMENTAL
Intervention: Single oral dose of [(14)C]pazopanib in suspension (400 mg, 70 µCi)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 5 mg pazopanib followed by oral administration of 800 mg pazopanib tablet once daily for 26 days
Number of subjects: 10
Study: 23548728

Group type: EXPERIMENTAL
Intervention: Antithyroid therapy (ATT) for 4 months
Number of subjects: 10
Study: 23548879

Group type: EXPERIMENTAL
Intervention: Intravenous synthetic human secretin (sHS) 0.05-0.8 µg/kg for 3 days
Number of subjects: 12
Study: 23549489

Group type: EXPERIMENTAL
Intervention: In-hospital management of patients on warfarin undergoing PCI-S
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Triple therapy (warfarin, aspirin, and clopidogrel) prescription at discharge
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Non-low thromboembolic risk
Number of subjects: 411
Study: 23550096

Group type: EXPERIMENTAL
Intervention: Intracoronary sodium nitrite
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 80
Study: 23551108

Group type: EXPERIMENTAL
Intervention: High-protein drink (325 mL) with ice chips/water PRN
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ice chips/water PRN (Control)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-protein drink (325 mL)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ice chips/water (Control)
Number of subjects: 150
Study: 23551593

Group type: EXPERIMENTAL
Intervention: everolimus 10 mg orally once daily continuously (one cycle = 4 weeks)
Number of subjects: 45
Study: 23551918

Group type: EXPERIMENTAL
Intervention: rFVIIa administration for joint bleeds in children
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: rFVIIa administration for joint bleeds in adults
Number of subjects: 52
Study: 23551933

Group type: EXPERIMENTAL
Intervention: 2009 trivalent inactivated split-virion influenza vaccine (TIV) 0.25 ml (22.5 μg haemagglutinin) or 0.5 ml (45 μg) depending on age and prior vaccination history
Number of subjects: 1992
Study: 23552982

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with grades III and IV toxic effects
Number of subjects: 2670

Group type: EXPERIMENTAL
Intervention: Metastatic disease at diagnosis
Number of subjects: 2670

Group type: EXPERIMENTAL
Intervention: Poor tolerance of neoadjuvant treatment
Number of subjects: 2670

Group type: EXPERIMENTAL
Intervention: Centers performing at least 10 resections per year
Number of subjects: 2670
Study: 23553066

Group type: EXPERIMENTAL
Intervention: Combination of oxaliplatin (100 mg/m2), docetaxel (35 mg/m2), and vandetanib (100 mg PO daily)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of oxaliplatin (80 mg/m2), docetaxel (30 mg/m2), and vandetanib (100 mg PO daily)
Number of subjects: 9
Study: 23553119

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel, 0.015%, daily for 3 consecutive days for face or scalp lesions.
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel, 0.05%, daily for 2 consecutive days for trunk or extremity lesions.
Number of subjects: 184
Study: 23553159

Group type: EXPERIMENTAL
Intervention: Fava beans (dietary intervention)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control diet (fixed-sodium diet)
Number of subjects: 13
Study: 23553162

Group type: EXPERIMENTAL
Intervention: Raw fruit consumption
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Citrus fruit intake
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Apple intake
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Banana intake
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Fruit juice intake
Number of subjects: 4680
Study: 23553164

Group type: EXPERIMENTAL
Intervention: High dietary disinhibition (HD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low dietary disinhibition (LD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (HD and LD)
Number of subjects: 30
Study: 23553682

Group type: EXPERIMENTAL
Intervention: Total body computed tomography (TB-CT) scan
Number of subjects: 240
Study: 23553848

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cabozantinib 20 mg daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cabozantinib 100 mg daily
Number of subjects: 34
Study: 23554030

Group type: EXPERIMENTAL
Intervention: Vorinostat (300 mg/m²/day) and Temozolomide (150 mg/m²/day)
Number of subjects: 19
Study: 23554856

Group type: EXPERIMENTAL
Intervention: qPCR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PfHRP-2 ELISA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: pLDH ELISA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 30
Study: 23555538

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Ticlopidine (200 mg/day)
Number of subjects: 431
Study: 23555589

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 195
Study: 23557023

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort SMART(®), 160/4.5 μg) twice daily plus as needed
Number of subjects: 862
Study: 23557378

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (MV)
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Acute respiratory distress syndrome (ARDS)
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Cumulative fluid balance over the first 72 hours of ICU
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Higher lactate levels
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Severity of associated organ dysfunctions
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Positive fluid balance
Number of subjects: 773
Study: 23557395

Group type: EXPERIMENTAL
Intervention: Stent covering of the side branch (group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 98
Study: 23557744

Group type: EXPERIMENTAL
Intervention: Healthy eyes
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Glaucoma suspects
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Early glaucoma
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Moderate glaucoma
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Advanced glaucoma
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Correlation between CDR measurements
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: RGC estimates and CDR relationship
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Change in CDR
Number of subjects: 336
Study: 23557757

Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg/day) for 16 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (non-insulin-resistant women), n = 5
Number of subjects: 7
Study: 23557820

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 31
Study: 23557866

Group type: EXPERIMENTAL
Intervention: Gentamicin or Amikacin
Number of subjects: 0
Study: 23557865

Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia with fentanyl
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms (OPRM1 118A>G, ABCB1 2677G>A/T, ABCB1 3435C>T, CYP3A4*18, CYP3A5*3)
Number of subjects: 196
Study: 23558394

Group type: EXPERIMENTAL
Intervention: Citalopram (20-40 mg/day) during level 1 treatment
Number of subjects: 1928

Group type: EXPERIMENTAL
Intervention: Switch to sertraline, sustained-release bupropion, or extended-release venlafaxine or augmentation with sustained-release bupropion or buspirone during level 2 treatment
Number of subjects: 1928

Group type: EXPERIMENTAL
Intervention: Initial treatment responders
Number of subjects: 1928

Group type: EXPERIMENTAL
Intervention: Second-step treatment responders
Number of subjects: 1928

Group type: EXPERIMENTAL
Intervention: Patients with treatment resistance
Number of subjects: 1928
Study: 23558599

Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Elbow flexor muscle strength
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quadriceps peak torque
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hamstrings peak torque
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Maximal inspiratory pressure
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fatigue Assessment Scale
Number of subjects: 90
Study: 23558660

Group type: EXPERIMENTAL
Intervention: Zilver Vena stent
Number of subjects: 20
Study: 23558847

Group type: EXPERIMENTAL
Intervention: Implementation science principles and frameworks applied in intervention research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Established programs in hospice and palliative care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Well-tested programs introduced in new settings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions maximizing cost-effectiveness
Number of subjects: 0
Study: 23559086

Group type: EXPERIMENTAL
Intervention: Oral macimorelin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Arginine+GHRH
Number of subjects: 98
Study: 23559355

Group type: EXPERIMENTAL
Intervention: High-profile breast implants
Number of subjects: 4412

Group type: COMPARATOR
Intervention: Low- to moderate-profile breast implants
Number of subjects: 4412
Study: 23560296

Group type: EXPERIMENTAL
Intervention: Affected body surface area (BSA) > 25%
Number of subjects: 1541

Group type: EXPERIMENTAL
Intervention: Affected body surface area (BSA) > 25% and vitiligo lesions in the genital area
Number of subjects: 1541
Study: 23560297

Group type: EXPERIMENTAL
Intervention: Psoriatic children (n=155) with excess adiposity (body mass index ≥85th percentile)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Psoriatic children (n=155) with obesity (body mass index ≥95th percentile)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Severe psoriasis children (n=43)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Mild psoriasis children (n=27)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group (n=42)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Psoriatic children (n=409)
Number of subjects: 409
Study: 23560574

Group type: EXPERIMENTAL
Intervention: NeuroBlate System (laser interstitial thermal therapy)
Number of subjects: 10
Study: 23561231

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI), treated for 12 weeks
Number of subjects: 2280
Study: 23562618

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation to the supero-lateral branch of the medial forebrain bundle
Number of subjects: 7
Study: 23562852

Group type: EXPERIMENTAL
Intervention: Citalopram (20-60mg/day) for 8 weeks
Number of subjects: 201
Study: 23563126

Group type: EXPERIMENTAL
Intervention: Focal Impulse and Rotor Modulation (FIRM) followed by conventional ablation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional ablation alone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: All sources ablated
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Some sources ablated
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: No sources ablated
Number of subjects: 101
Study: 23563210

Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy (docetaxel, cyclophosphamide, followed by doxorubicin) every 3 weeks for 4 cycles, then surgery, followed by bevacizumab every 3 weeks for 9 cycles.
Number of subjects: 40
Study: 23564195

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy for CAP patients (mean duration = 11.1 days)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy for AECOPD patients (mean duration = 8.9 days)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 362

Group type: COMPARATOR
Intervention: Urinary antigen tests for Legionella pneumophila
Number of subjects: 362

Group type: COMPARATOR
Intervention: Sputum investigation
Number of subjects: 362
Study: 23564936

Group type: EXPERIMENTAL
Intervention: GP-organised follow-up
Number of subjects: 110
Study: 23564997

Group type: EXPERIMENTAL
Intervention: Central fat mass (CFM) assessment via DEXA in subjects with OSAS (AHI ≥ 15)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for mild OSAS cases (15 < AHI < 30)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for severe OSAS cases (AHI > 30)
Number of subjects: 749
Study: 23565175

Group type: EXPERIMENTAL
Intervention: Isometric knee extensor strength
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Isokinetic (60°/s) knee extensor strength
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Isokinetic (60°/s) knee flexor strength
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Isometric knee extensor strength (adjusted for age, sex, pain severity, BMI, peak VO2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Isokinetic knee extensor strength (adjusted for age, sex, pain severity, BMI, peak VO2)
Number of subjects: 69
Study: 23565181

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg BID for 8 weeks
Number of subjects: 20
Study: 23565931

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for hypertension
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for hyperglycaemia
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for dyslipidaemia
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: CVD risk profile
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Treatment targets for haemoglobin A1c, LDL, HDL, non-HDL cholesterol, systolic BP, BMI, waist circumference
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Unmet therapeutic targets
Number of subjects: 15773
Study: 23566357

Group type: EXPERIMENTAL
Intervention: Minocycline (1.4 mg/kg for six months)
Number of subjects: 11
Study: 23566574

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23567354

Group type: EXPERIMENTAL
Intervention: PDS (Postprandial Distress Syndrome)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: EPS (Epigastric Pain Syndrome)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: PDS and EPS overlap
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Functional Dyspepsia
Number of subjects: 138
Study: 23568645

Group type: EXPERIMENTAL
Intervention: Standard clinical management for heart failure (HF) including 12-lead ECG and transthoracic echocardiography at baseline, followed over 3 years.
Number of subjects: 5000
Study: 23569312

Group type: EXPERIMENTAL
Intervention: PD0332991 200 mg orally once per day for 14 consecutive days in 21-day cycles
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PD0332991
Number of subjects: 30
Study: 23569315

Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg loading, then 2 mg/kg once per week) and lapatinib (1000 mg once per day for 12 weeks)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Trastuzumab and lapatinib with letrozole (plus LHRH agonist if premenopausal) for ER-positive tumors
Number of subjects: 66
Study: 23572214

Group type: EXPERIMENTAL
Intervention: Transanal endoscopic total mesorectal excision (TME) with laparoscopic assistance
Number of subjects: 5
Study: 23572474

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study: 23573223

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 0
Study: 23574119

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Retrospective analysis of DA-EPOCH-R
Number of subjects: 51
Study: 23574764

Group type: EXPERIMENTAL
Intervention: Computerized Clinical Decision Support System (CDSS) for antenatal care and care during delivery and up to 24 hours post delivery.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDSS implementation in rural primary health care centers.
Number of subjects: 0
Study: 23575255

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 3207

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3207
Study: 23575256

Group type: EXPERIMENTAL
Intervention: Fasting insulin levels
Number of subjects: 4425
Study: 23575334

Group type: EXPERIMENTAL
Intervention: VNTR typing of M. intracellulare
Number of subjects: 70
Study: 23575363

Group type: EXPERIMENTAL
Intervention: CD34+/KDR+/CD45- cells
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: CD133+/KDR+/CD45- cells
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Increase in CD34+/KDR+/CD45- cells
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Increase in CD133+/KDR+/CD45- cells
Number of subjects: 155
Study: 23575918

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Postmenopausal comparison group (no AIs)
Number of subjects: 268
Study: 23576045

Group type: EXPERIMENTAL
Intervention: Dietary intake of riboflavin, folate, choline, and betaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Blood biomarkers of riboflavin, vitamin B-6, active vitamin B-12 (holotranscobalamin), and betaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation analysis between dietary intakes and blood biomarkers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Seasonal switch between the betaine and folate pathways
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Natural variations in food-consumption patterns
Number of subjects: 30
Study: 23576267

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment twice weekly for 4 weeks
Number of subjects: 33
Study: 23576625

Group type: EXPERIMENTAL
Intervention: CERE-120 (AAV2-neurturin) administered bilaterally to the substantia nigra and putamen
Number of subjects: 6
Study: 23577182

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg twice daily for 4 weeks
Number of subjects: 6
Study: 23578144

Group type: EXPERIMENTAL
Intervention: Peptide vaccine therapy using a mixture of four novel peptides (VEGFR1, VEGFR2, URLC10, TTK/CDCA1) administered weekly by subcutaneous injection with montanide ISA-51 adjuvant.
Number of subjects: 15
Study: 23578775

Group type: EXPERIMENTAL
Intervention: Migraine attacks
Number of subjects: 78
Study: 23578816

Group type: EXPERIMENTAL
Intervention: Commercial EHR with robust clinical decision support (CDS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: System refinements in EHR
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Commercial EHR with advanced CDS
Number of subjects: 16
Study: 23578923

Group type: EXPERIMENTAL
Intervention: Irisin levels
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Interventions designed to increase irisin action
Number of subjects: 17
Study: 23579255

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Electric scalpel (ES)
Number of subjects: 95